••			)	71-TDC
N .			P	/ DOC
QUERY CONTROL FORM			RTIS USE ONLY	
Application No. 09/92(0, 41)	Prepared by	DUP.	Tracking Number	06012951
Examiner-GAU AZDURU-1015	Date	10126/04	Week Date	09/20/04
	No. of queries	, ,	IFW(G)	<del></del>

JACKET					
a. Serial No.	f. Foreign Priority	k. Print Claim(s)	p. PTO-1449		
b. Applicant(s)	g. Disclaimer	I. Print Fig.	q. PTOL-85b		
c. Continuing Data	h. Microfiche Appendix	m. Searched Column	r. Abstract		
d. PCT	i. Title	n. PTO-270/328	s. Sheets/Figs		
e. Domestic Priority	j. Claims Allowed	o. PTO-892	t. Other		

SPECIFICATION	MESSAGE Improver Dependency: in the claim set.
a. Page Missing	Claim 2 (renumbered Claim D) is dependent upon
b. Text Continuity	larger Claim be brenumbered Claim 4) and Claim 4
c. Holes through Data	-trenumbered Claim 3), -see offached.
d. Other Missing Text	
e. Illegible Text	please advise correct claim dependency
f. Duplicate Text	(renumber the chims if recessory).
g. Brief Description	7, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3,
h. Sequence Listing	
i. Appendix	
j. Amendments	
k. Other	
CLAIMS	
a. Claim(s) Missing	
b. Improper Dependency	
c. Duplicate Numbers	Thank Yaz
d. Incorrect Numbering	initials DUP
e. Index Disagrees	RESPONSE
f. Punctuation	
g. Amendments	
h. Bracketing	
i. Missing Text	
j. Duplicate Text	
k. Other	
	initials

U.S. Application No.: 09/926,411

Reply to Office Action dated August 7, 2003

## LISTING OF THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application.

Claim 1 (canceled)

Claim 2 (previously presented): The method of claim 8, wherein the macrolide compound is a tricyclo compound (I) of the following formula

wherein

adjacent pairs of R1 and R2, R3 and R4, and R5 and R6 each independently

- a) consist of two adjacent hydrogen atoms, wherein R<sup>2</sup> is optionally alkyl, or
- b) form another bond between carbon atoms binding with the members of each pair;

U.S. Application No.: 09/926,411 Reply to Office Action dated August 7, 2003

or a pharmaceutically acceptable salt thereof.

Claim 2 (previously presented): The method of claim 6 or claim 2, wherein said macrolide compound is FK506.

Claim (currently amended): The method of claim s, wherein said macrolide compound is administered in the form of a preparation suitable for local administration to the eye as an eye drop.

Claim 5 (canceled)

Claim (currently amended): A method for treating a dry eye, comprising administering ocular administration of an effective amount of a macrolide compound to a subject in need of the treatment of dry eye.

Claim 7 (canceled)

Claim & (previously presented): The method of claim &, wherein said macrolide compound is administered in the form of a preparation suitable for local administration.